Literature DB >> 20535144

Pazopanib trial data cannot support first-line use.

Claudio Jeldres, Maxine Sun, Paul Perrotte, Pierre I Karakiewicz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20535144     DOI： 10.1038/nrurol.2010.65

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.

Authors:  Thomas E Hutson; Ian D Davis; Jean-Pascal H Machiels; Paul L De Souza; Sylvie Rottey; Bao-Fa Hong; Richard J Epstein; Katherine L Baker; Lauren McCann; Theresa Crofts; Lini Pandite; Robert A Figlin
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

4.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

5.  Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Authors:  Brian I Rini; Susan Halabi; Jonathan E Rosenberg; Walter M Stadler; Daniel A Vaena; San-San Ou; Laura Archer; James N Atkins; Joel Picus; Piotr Czaykowski; Janice Dutcher; Eric J Small
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

6.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

7.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors:  Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Journal:  Lancet       Date:  2008-07-22       Impact factor: 79.321

8.  Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.

Authors:  Sylvie Negrier; David Perol; Alain Ravaud; Christine Chevreau; Jacques-Olivier Bay; Remy Delva; Emmanuel Sevin; Armelle Caty; Bernard Escudier
Journal:  Cancer       Date:  2007-12-01       Impact factor: 6.860

9.  Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

Authors:  Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544
  9 in total
  3 in total

1.  Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.

Authors:  Daniel Canter; Alexander Kutikov; Konstantin Golovine; Petr Makhov; Jay Simhan; Robert G Uzzo; Vladimir M Kolenko
Journal:  Can J Urol       Date:  2011-08       Impact factor: 1.344

Review 2.  Molecular targeted approaches for treatment of pancreatic cancer.

Authors:  Z Q Huang; A K Saluja; V Dudeja; S M Vickers; D J Buchsbaum
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

3.  Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.

Authors:  Naveen S Vasudev; James M G Larkin
Journal:  Clin Med Insights Oncol       Date:  2011-10-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.